Treatment of Multiple Myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Sonneveld P et al. Blood. 2016 Mar 21. pii: blood-2016-01-631200. [Epub ahead of print].
Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma.
Wahaib K et al. Am J Health Syst Pharm. 2016 Apr 1;73(7):441-50. doi: 10.2146/ajhp150487.
Haematological cancer: PomCyDex – a lower-cost option in refractory myeloma?
Killock D et al. Nat Rev Clin Oncol. 2016 Mar 22. doi: 10.1038/nrclinonc.2016.47. [Epub ahead of print].
Mixed outpatient-inpatient autologous stem cell transplant for multiple myeloma: A cost-saving initiative in a resource constrained environment.
Clemmons AB et al. J Oncol Pharm Pract. 2016 Mar 21. pii: 1078155216639753. [Epub ahead of print].
Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.
Hong S et al. Biol Blood Marrow Transplant. 2016 Mar 16. pii: S1083-8791(16)00160-9. doi: 10.1016/j.bbmt.2016.03.011. [Epub ahead of print].
The Ethical Challenges of Compassionate Use.
Caplan AL et al. JAMA. 2016 Mar 8;315(10):979-80. doi: 10.1001/jama.2016.0416.
Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?
Mian M et al. Anticancer Res. 2016 Mar;36(3):1059-65.
Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma.
Hoy SM. Target Oncol. 2016 Mar 14. [Epub ahead of print].
Short- and long-term outcomes in onco-hematological patients admitted to the intensive care unit with classic factors of poor prognosis.
Faucher E et al. Oncotarget. 2016 Mar 8. doi: 10.18632/oncotarget.7986. [Epub ahead of print].
Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation MyelomaTherapeutics.
Willenbacher E et al. PLoS One. 2016 Mar 3;11(3):e0147381. doi: 10.1371/journal.pone.0147381. eCollection 2016.
Life beyond bortezomib: increasing treatment options in refractory myeloma.
Chakraborty R et al. Leuk Lymphoma. 2016 Mar 1:1-3. [Epub ahead of print].
Ixazomib: First Global Approval.
Shirley M. Drugs. 2016 Mar;76(3):405-11. doi: 10.1007/s40265-016-0548-5.
MRD-driven treatment paradigm for newly diagnosed transplant eligible multiple myeloma patients.
Landgren O et al. Bone Marrow Transplant. 2016 Feb 29. doi: 10.1038/bmt.2016.24. [Epub ahead of print].
Signaling Pathways and Emerging Therapies in Multiple Myeloma.
Ramakrishnan V et al. Curr Hematol Malig Rep. 2016 Feb 27. [Epub ahead of print].
Low levels of circulating adiponectin are associated with multiple myeloma risk in overweight and obese individuals.
Hofmann JN et al. Cancer Res. 2016 Feb 26. pii: canres.2406.2015. [Epub ahead of print].
The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
Caers J et al. Oncologist. 2016 Mar;21(3):333-42. doi: 10.1634/theoncologist.2015-0303. Epub 2016 Feb 26.
Risk factors for progression from smoldering into active myeloma: additional insights from a population-based study.
Castillo JJ. Eur J Haematol. 2016 Feb 26. doi: 10.1111/ejh.12750. [Epub ahead of print].
New Monoclonal Antibody Approved to Treat Multiple Myeloma.
Aschenbrenner DS. Am J Nurs. 2016 Mar;116(3):22. doi: 10.1097/01.NAJ.0000481274.07310.b9.
Cognitive and Situational Precipitants of Loneliness Among Patients With Cancer: A Qualitative Analysis.
Adams RN et al. Oncol Nurs Forum. 2016 Mar 1;43(2):156-63. doi: 10.1188/16.ONF.156-163.
Reprint of: Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.
Perales MA et al. Biol Blood Marrow Transplant. 2016 Mar;22(3 Suppl):S9-S14. doi: 10.1016/j.bbmt.2016.01.005.